Journal article icon

Journal article

Development of a T cell receptor mimic antibody against wild-type p53 for cancer immunotherapy

Abstract:

The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Due to its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful class of anti-cancer drugs. However, peptides derived from intracellular antigens are presented on the cell surface in the context of major histocompatibility class I (MHC I), and can be bound by T cell receptors (TCRs). Here, we report the developme...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1158/0008-5472.CAN-16-3247

Authors


More by this author
Department:
Oxford, MSD, RDM, RDM Clinical Laboratory Sciences, Biomedical Research Centre
More by this author
Department:
Oxford, MSD, RDM, RDM Clinical Laboratory Sciences
More by this author
Department:
Oxford, MSD, RDM, RDM Clinical Laboratory Sciences
Cleary, KLS More by this author
Expand authors...
More from this funder
Funding agency for:
Koustoulidou, S
More from this funder
Funding agency for:
Banham, AH
Expand funders...
Publisher:
American Association for Cancer Research Publisher's website
Journal:
Cancer Research Journal website
Volume:
77
Issue:
10
Pages:
2699-2711
Publication date:
2017-03-31
Acceptance date:
2017-03-09
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
Pubs id:
pubs:688621
URN:
uri:204933be-d729-4354-9dd9-e457b15610bb
UUID:
uuid:204933be-d729-4354-9dd9-e457b15610bb
Local pid:
pubs:688621

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP